Form 4 Filing for Opus Genetics, Inc. - Insider Transaction

Amy Rabourn, Head of Fin. Quality Assurance at Opus Genetics, Inc., reported a sale of 1641 shares of Common Stock on April 23, 2026. The sale was executed automatically to cover tax withholding obligations arising from a restricted stock units award vesting and settlement event. This transaction was not discretionary. The weighted average selling price was approximately $5.204, with individual sales ranging from $5.2038 to $5.2051. Following this transaction, Ms. Rabourn directly owns 188,671 shares of Common Stock.